Amedisys, Inc. (NASDAQ:AMED) Stock Position Decreased by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 70.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,800 shares of the health services provider's stock after selling 84,301 shares during the period. Renaissance Technologies LLC owned about 0.11% of Amedisys worth $3,250,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Blue Trust Inc. boosted its stake in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares during the period. HBW Advisory Services LLC purchased a new stake in Amedisys in the fourth quarter worth $38,000. Versant Capital Management Inc grew its stake in shares of Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after acquiring an additional 183 shares during the period. Vestcor Inc bought a new stake in Amedisys during the fourth quarter valued at approximately $73,000. Finally, Venturi Wealth Management LLC lifted its holdings in Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after purchasing an additional 779 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Stock Up 0.2 %

Amedisys stock traded up $0.17 during mid-day trading on Tuesday, hitting $94.86. The company had a trading volume of 111,020 shares, compared to its average volume of 405,030. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The business has a fifty day moving average of $92.25 and a 200 day moving average of $91.74. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 37.64, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business's revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.03 EPS. On average, sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AMED has been the subject of several recent analyst reports. Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.